Black Diamond Therapeutics, Inc.

BDTX Healthcare Biotechnology

Black Diamond Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.0 million. In the quarter to June 2026, EPS grew 10.5% and free cash flow grew 12.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.72 0.02 −1.15%
Market cap
$100.0M
P/E
0.0×
Fwd P/E
−3.0×
Dividend yield
—
F-score
n/a
Altman Z
−0.10
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
8.94 8.42 8.46 7.28
Net Debt/EBITDA
12.44 7.33 10.53 9.19
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.14) (0.12) (0.18) (0.14)
Book value per Share
2.22 1.97 1.82 1.68
Free Cash Flow
(7.85) (6.78) (10.23) (7.97)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates